Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study
Authors' conclusion
Hypogammaglobulinaemia following RTX is uncommon in IIM and is not related to any clinical variables, including GC dosage and previous treatments.
Study context
- Population
- Patients with idiopathic inflammatory myopathies (IIM) evaluated in the Myositis clinics of Siena, Bari and Palermo University Hospitals, treated for the first time with rituximab (RTX)22 female
- Participants
- 30 patients
- Outcome
- Changes in Ig levels during RTX treatment and their association with infections
- Follow-up
- 6 (T1) and 12 (T2) months
Methodological detailsthree Italian university hospitals
- Three Italian university hospitals
Main finding
As reported in the abstract
Ig levels during RTX treatment
- Low IgG (<700 mg/dl), proportion of patients
- 10%
- Low IgM (<40 mg/dl), proportion of patients
- 17%
- Severe hypogammaglobulinaemia (IgG<400 mg/dl)
- 0
- IgA lower at T1 than T0
- p=0.0218
- IgG lower at T2 than baseline
- p=0.0335
- IgM lower at T1 and T2 than T0
- p<0.0001
- IgM lower at T2 than T1
- p=0.0215
Observational data: associations, not effects.
Further findings
Correlation of glucocorticoid (GC) dosage at T0 with IgA at T0
- Inverse correlation, r
- - 0.514
- P
- P = 0.004
Correlation of demographic, clinical and treatment variables with immunoglobulin (Ig) serum levels
- No correlation found
Safety
- Major infections, patients
- 3
- Paucisymptomatic COVID-19, patients
- 2
- Mild zoster, patients
- 1
Original publication
Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study. Clin Exp Rheumatol. Published 29 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →